Celgene Corporation 보도자료
Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
03월 21일 13:15
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that additional data of exploratory endpoints from the T...
Oral OTEZLA® (Apremilast) Long-Term Safety Data Presented at American Academy of Dermatology Congress
03월 08일 12:15
Celgene Corporation (NASDAQ: CELG) today announced that long-term safety findings from ongoing clinical trials of OTEZLA® (apremilast), the Company‘s oral, selective...
Oral OTEZLA® (apremilast) Data from Open-Label Phase of ESTEEM and LIBERATE™ Trials to Be Presented at American Academy of Dermatology Congress
03월 07일 10:05
Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical trials of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phos...
Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS
02월 19일 14:10
Celgene Corporation (NASDAQ:CELG) today announced 72-week results from the RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modu...
경구용 ‘오자니모드’의 궤양성 대장염 환자 대상 ‘TOUCHSTONE’ 2상 유지치료 시험 결과, 통합 유럽 위장병학(UEG) 주간 행사서 발표
2015년 10월 27일
세엘진 코퍼레이션(Celgene Corporation)(나스닥: CELG)의 완전 소유 자회사인 세엘진 인터내셔널(Celgene International Sàrl)이 오늘 스페인 바르셀로나에서 개최된 통합 유럽 위장병학 주간(United European Gastroenterology [UEG]W...
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week
2015년 10월 27일
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today presented results from the maintenance phase of the TOUCHSTONE pha...
궤양성 대장염 환자에 대한 경구형 오자니모드 TOUCHSTONE 연구 임상2상 시험 유지 데이터 발표···ACT 총회
2015년 10월 20일
세엘진코퍼레이션(Celgene Corporation)(나스닥: CELG)이 오늘 호놀룰루에서 개최된 미국소화기학회(American College of Gastroenterology, 약칭 ACG) 연례학술대회에서 중등도~중증 궤양성 대장염 환자를 대상으로 한 임상시험물질 ‘오자니모드’(Ozani...
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
2015년 10월 20일
Celgene Corporation (NASDAQ: CELG) today announced detailed results from the maintenance phase of the TOUCHSTONE phase 2 clinical trial of Ozanimod, an investigation...
Oral Presentation Evaluating Pooled Data on OTEZLA® (apremilast) for Long-Term Improvements in Enthesitis and Dactylitis to Be Presented at EULAR
2015년 06월 10일
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the findings from a long-term (104-week) post-hoc an...
Celgene Announces New Data to be Presented at European League Against Rheumatism Annual Congress
2015년 06월 04일
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that data from 11 abstracts (two oral presentations, six ...
Analysis of Phase II Data for Celgene’s Investigational Oral GED-0301 in Patients with Active Crohn’s Disease Presented at Digestive Disease Week
2015년 05월 20일
Celgene Corporation (NASDAQ: CELG) today announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of...
Phase II Data for Apremilast in Behçet’s Disease Published in The New England Journal of Medicine
2015년 04월 16일
Celgene Corporation (NASDAQ:CELG) today announced that results from a multicenter, randomized, placebo-controlled phase II trial (BCT-001) of apremilast (Otezla®) in...
Positive Results from Phase III Study Evaluating Oral OTEZLA® (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD
2015년 03월 23일
Celgene Corporation (NASDAQ:CELG) today announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company’s oral, selecti...
Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD
2015년 03월 23일
Celgene Corporation (NASDAQ: CELG) today announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla®...
Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine
2015년 03월 19일
Celgene Corporation (NASDAQ:CELG) today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (monger...
1 2 3 >
Celgene Corporation
상장여부 : 비상장
본사 소재지 : SUMMIT, N.J.
업종: 건강-제약
웹사이트: http://www.celgene.com
기업 개요:
등록된 회사소개가 없습니다.